Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom

C McKenna,¹ S Palmer,¹ M Rodgers,² D Chambers,² N Hawkins,¹ S Golder,² S Van Hout,¹ C Pepper,³ D Todd,⁴ N Woolacott²

¹ Centre for Health Economics, University of York, York, UK; ² Centre for Reviews and Dissemination, University of York, York, UK; ³ Yorkshire Heart Centre, Leeds, UK; ⁴ The Cardiothoracic Centre, Liverpool NHS Trust, UK

Correspondence to: Dr Claire McKenna, Centre for Health Economics, Alcuin 'A' Block, University of York, Heslington, York YO10 5DD, UK; cm535@york.ac.uk

Accepted 24 November 2008
Published Online First
18 December 2008

ABSTRACT

Objective: To assess the cost-effectiveness of radiofrequency catheter ablation (RFCA) compared with anti-arrhythmic drug (AAD) therapy for the treatment of atrial fibrillation (AF) from the perspective of the UK NHS.

Design: Bayesian evidence synthesis and decision analytical model.

Methods: A systematic review and meta-analysis was conducted and Bayesian statistical methods used to synthesise the effectiveness evidence from randomised control trials. A decision analytical model was developed to assess the costs and consequences associated with the primary outcome of the trials over a lifetime time horizon.

Main outcome measure: Costs from a health service perspective and outcomes measured as quality-adjusted life years (QALYs).

Results: The incremental cost-effectiveness ratio of RFCA varied between £7763 and £7910 for each additional QALY according to baseline risk of stroke, with a probability of being cost-effective from 0.98 to 0.99 for a cost-effectiveness threshold of £20 000. Results were sensitive to the duration of quality of life benefits from treatment.

Conclusions: RFCA is potentially cost-effective for the treatment of paroxysmal AF in patients' predominantly refractory to AAD therapy provided the quality-of-life benefits from treatment are maintained for more than 5 years. These findings remain subject to limitations in the existing evidence regarding the nature of life benefits and the prognostic importance of restoring normal sinus rhythm conferred using RFCA.

Atrial fibrillation (AF) is a common and debilitating cardiac arrhythmia. Its prevalence in the United Kingdom is rising as a result of an ageing population and an increased longevity resulting from improved medical care for chronic cardiac conditions which predispose to AF.¹ A recent report estimated that approximately 1% of all NHS expenditures are the result of AF.² The cost-effective management of AF in the United Kingdom therefore represents an important consideration.

Radiofrequency catheter ablation (RFCA) is an established technique for the treatment of cardiac arrhythmias, which has relatively recently been extended to allow treatment of AF. In the United Kingdom, its use for controlling AF is recommended by the National Institute for Health and Clinical Excellence (NICE) for patients who have previously failed on other management strategies.³

RFCA offers the potential to eliminate the underlying cause of AF, which other therapies fail to achieve. The primary outcome from the procedure is the restoration and maintenance of normal sinus rhythm (NSR). The sustained long-term maintenance of sinus rhythm establishes the efficacy of the intervention.

RFCA results in significant upfront costs and a risk of procedural complications. However, the potential quality-of-life benefits through long-term absence of arrhythmia and any associated prognostic benefits (for example, reduced risk of stroke) may outweigh the costs when compared to long-term use of anti-arrhythmic drug (AAD) therapy and its associated adverse effects. Only one previous study, based on a US population, has examined the cost-effectiveness of RFCA for AF.⁴ Our aim was to develop a UK-specific cost-effectiveness model of RFCA compared with AADs for patients predominantly refractory to at least one previous AAD.

METHODS

Overview

A probabilistic decision analytical model was developed to assess the cost-effectiveness of RFCA in the UK National Health Service. A systematic review and meta-analysis was conducted and Bayesian statistical methods used to synthesise the effectiveness evidence from randomised control trials (RCTs). The model considers the short-term and long-term costs and consequences associated with the primary outcome of the trials: freedom from arrhythmia at 12 months.

The structure of the decision analytical model and its underlying assumptions were developed in discussion with UK clinical advisers. Outcomes in the model were expressed in terms of quality-adjusted life years (QALYs). Costs were considered from the perspective of the UK NHS and Personal Social Services, using 2006 prices, with costs and benefits discounted at 3.5% per year.⁵

Treatment strategies and population

The decision model evaluates the cost-effectiveness of RFCA in adults with AF refractory to at least one AAD. It evaluates a strategy of RFCA (without long-term AAD use) compared to long-term AAD treatment alone. The AAD considered is amiodarone, selected on the basis that this drug is most likely to be given after patients have previously failed on other AADs in routine practice. The

Figure 1 (A) Structure of the short-term model. Schematic of pathways leading to the two main starting health states (normal sinus rhythm (NSR)/atrial fibrillation (AF)) of the long-term Markov model. (B) Structure of the long-term Markov model. Additional states were incorporated for the antiarrhythmic drug (AAD) strategy because of potential adverse toxicity events.

majority of subjects included in the RCTs had paroxysmal AF as opposed to persistent or permanent forms.

Model structure

The decision model comprised two components: a decision tree that captured the short-term clinical outcomes and costs associated with the treatment strategies up to a period of 12 months; and a long-term Markov model, which extrapolates the costs and outcomes over a lifetime time horizon using

annual cycles. Figure 1 provides a schematic of the model structure.

For RFCA, the risk of operative death or procedural complications, including cardiac tamponade, stroke and pulmonary vein (PV) stenosis, were modelled. For AADs, the risk of adverse drug toxicity (both reversible and irreversible) was considered. In addition, a risk of pulmonary complications given withdrawal from treatment because of an acute episode of toxicity, was modelled. An elevated risk of mortality was also

assumed to be associated with an irreversible event. Several competing risks including stroke, adverse bleeding events (due to concomitant medications), and other causes of mortality were also included in the short-term model for both treatment strategies. At the end of the 12-month period, the short-term model established the proportion of patients that entered the two main starting health states of the long-term extrapolation model, after accounting for mortality and the risk of stroke: NSR (that is, restoration to normal sinus rhythm) and AF (that is, reversion to atrial fibrillation).

The long-term model took the form of a Markov process with health states for NSR, AF, stroke and death. The potential adverse drug toxicity events associated with the use of AADs required additional states in the AAD model. Patients in the NSR state faced an annual probability of reversion back to AF and an elevated risk of stroke compared to the general population. Patients in the AF state were assumed to be withdrawn from treatment and faced a higher risk of stroke than NSR patients. Patients surviving the first year of a stroke entered a post-stroke state, where the risk of death due to stroke and the costs incurred from stroke were lower than in the first year of the event. In each yearly cycle, all patients regardless of their current health state faced an annual risk of mortality from other causes (non-stroke mortality). In addition, the model included a cost and quality-of-life decrement associated with the risk of major and minor bleeding events from the use of concomitant medications.

Model inputs

Clinical effectiveness

Three separate analyses considering a range of alternative data sources were used to inform the clinical effectiveness inputs. The primary health outcome considered was freedom from AF at 12 months. These data were used to estimate the probability of NSR and AF for RFCA and AADs applied in the short-term model. Three randomised controlled trials (RCTs) were identified where RFCA was compared directly to AADs for patients with predominantly paroxysmal AF.⁶⁻⁸ In the absence of a single study with which to populate a UK baseline event rate for RFCA, evidence from a wider range of case series and survey data were considered. A number of individual case series were identified that reported the primary outcome at 12 months following RFCA. In addition, a worldwide survey was identified on the efficacy of RFCA.⁹

Bayesian meta-analytical approaches were used to synthesise the RCT evidence and the non-RCT data. A random baseline, fixed-effect model was used as the basis for the meta-analysis. Outcomes were estimated as freedom from AF by combining the weight of evidence from the RCTs and the external evidence. The base-case analysis establishes the cost-effectiveness of RFCA on the assumption that the average patient is treated as in the RCTs. Alternative scenarios were undertaken by combining the RCT evidence with the case series and survey data.

Table 1 summarises the main input variables and sources applied in the cost-effectiveness model. The various components are described below.

Long-term reversion rates (NSR to AF)

Central to the long-term model was the subsequent event rates (and costs and quality-of-life estimates) for patients who left the short-term model free of arrhythmia (NSR) or not (AF) at 12 months. The long-term reversion rates to AF represent

important parameters because any additional benefit assigned to NSR relative to AF is only maintained in the long term if patients continue to remain free of arrhythmia. In the absence of data from the RCTs of RFCA beyond 12 months of follow-up, these estimates were obtained from other sources. The annual rate of reversion for patients who receive RFCA was estimated from a large controlled study with a median follow-up of 900 days.¹⁰ The annual reversion rate for patients receiving AADs was estimated from a multicentre trial examining the long-term efficacy of amiodarone in preventing recurrent AF.¹¹

Stroke

The baseline risk of stroke for AF was based on the CHADS₂ index, which has been validated in a national registry of AF.¹² A numerical score is given to each of five risk factors (recent congestive heart failure, hypertension, age, diabetes mellitus, history of stroke or transient ischaemic attack), and the total score (≤ 6) equates to a stroke risk for AF. CHADS₂ is broadly similar to the risk stratification algorithm proposed by the National Institute for Health and Clinical Excellence (NICE), which stratifies subjects into low, moderate and high-risk categories.¹³

Consideration was also given as to whether the stroke risk was different according to NSR/AF status. No direct evidence from the RCTs was available to quantify the potential differential risk for NSR/AF. A separate search of the literature was undertaken to identify additional evidence related to the prognostic value of NSR in patients with AF. The search identified an analysis of the AFFIRM study, which examined the occurrence and characteristics of stroke events in their investigation of sinus rhythm management, and provided an estimate of the hazard of stroke for AF relative to NSR.¹⁴ Using a Cox proportional hazards regression analysis, the presence of AF was found to be significantly associated with a 60% increase in the risk of stroke after adjusting for several covariates including the use of warfarin therapy. This provided an estimate of the stroke risk reduction for NSR, which was lower than the risk for AF but remained higher than the general population.

To reduce thromboembolism in AF, most patients, regardless of treatment strategy, receive some form of anticoagulants or antiplatelets. The Euro Heart Survey on AF analysed current antithrombotic drug prescriptions.¹⁵ These data were used to estimate the proportion of patients likely to receive warfarin, aspirin or no oral anticoagulants (OACs) in the United Kingdom. Stroke risk reduction through the use of OACs was derived from a systematic review and meta-analysis of stroke prevention with warfarin and aspirin in patients with AF.¹³ The adjustments were applied to the stroke risk for NSR and AF derived from the CHADS₂ index.

Mortality

The model separates deaths into those caused by stroke, drug toxicity and other cause mortality. The mortality risk from stroke was derived from a UK-based Community Stroke Project, which examined the long-term prognosis after acute stroke.¹⁶ The age-dependent risk of other-cause mortality was based on standard UK age-specific and sex-specific mortality rates.¹⁷ The treatments were assumed not to infer a differential mortality effect, except through their reduction in the risk of stroke through NSR or AF.

Resource use and unit costs

The resources considered were based on the short-term and long-term events associated with each treatment strategy. The

Table 1 Summary of input parameters applied in the base-case model

Variables	Value	Low CI	High CI	Distribution	Ref
Probability of NSR at 1 year					
RFCA	0.8405	0.5579	0.9631	Posterior	
AADs	0.3682	0.1060	0.7083	Posterior	
Odds ratio	0.0968	0.0520	0.1641	Posterior	
Annual probability of recurrent AF after year 1					
RFCA	0.0335	0.0220	0.0451	Beta	10
AADs	0.2883	0.2323	0.3456	Beta	11
Stroke risk for AF (%)					
CHADS ₂ = 0	1.9	1.2	3.0	Beta	12
CHADS ₂ = 1	2.8	2.0	3.8	Beta	12
CHADS ₂ = 2	4.0	3.1	5.1	Beta	12
CHADS ₂ = 3	5.9	4.6	7.3	Beta	12
Hazard ratio relative to NSR*	1.60	1.11	2.30	Log normal	14
Stroke risk reduction with OACs (RR)					
Warfarin relative to placebo	0.33	0.24	0.45	Log normal	13
Warfarin relative to aspirin	0.59	0.40	0.86	Log normal	13
OAC use (%)					
Warfarin	64.0	—	—	Dirichlet	15
Aspirin	27.3	—	—	Dirichlet	15
None	8.7	—	—	Dirichlet	15
Mortality risk from stroke (RR)					
In year 1	7.40	6.50	8.50	Betapert	16
In subsequent years	2.30	2.00	2.70	Betapert	16
Adverse toxicity from AADs (%)					
General toxicity (year 1)	12.50	10.00	15.00	Betapert	22
General toxicity ($\geq$ 2 years)	6.25	5.00	7.50	Betapert	22
Withdrawal due to toxicity (year 1)	10.00	6.25	12.50	Betapert	22
Withdrawal due to toxicity ($\geq$ 2 years)	5.00	3.13	6.25	Betapert	22
Pulmonary complication given withdrawal	15.19	1.00	30.00	Betapert	22
Irreversible pulmonary complication	25.00	0.00	30.00	Betapert	22
Mortality from irreversible pulmonary event	20.00	5.00	25.00	Betapert	22
Adverse bleeding from OACs (%)					
Major bleed on warfarin	2.40	1.70	8.10	Betapert	26
Minor bleed on warfarin	15.80	15.00	16.60	Betapert	26
Bleeding risk reduction on aspirin (RR)					
Major bleed	0.58	0.35	0.97	Log normal	13
Minor bleed	0.45	0.32	0.64	Log normal	13
Bleeding risk reduction on no OACs (RR)					
Major bleed	0.45	0.25	0.82	Log normal	13
Minor bleed	0.46	0.36	0.59	Log normal	13
RFCA procedural complications (%)					
Operative death	0.05	0.00	0.09	Beta	9
Cardiac tamponade	1.22	0.99	1.45	Beta	9
Stroke	0.28	0.16	0.40	Beta	9
PV stenosis	0.74	0.54	0.94	Beta	9
Mean number of procedures per patient	1.304	1.293	1.315	Normal	9
Utilities associated with health states					
SE					
Decrement for NSR given RFCA	0.0000	—	30	—	27
Decrement for NSR given AADs	0.0199	0.0100	—	Gamma	27
Decrement for AF given RFCA	0.0034	0.0017	—	Gamma	28
Decrement for AF given AADs	0.0925	0.0361	—	Gamma	28
Disabled stroke	0.38	0.0460	—	Beta	19
Non-disabled stroke	0.74	0.0260	—	Beta	19
Combined stroke (30.9% disabled)	0.63	—	—	—	19
Decrement for pulmonary toxicity	0.0329	0.0030	—	Gamma	21
Decrement for non-pulmonary toxicity or bleeding event (days of perfect health lost)	1	0	—	Betapert	22
Unit costs (£)					
RFCA accumulated cost†	9810	—	—	Fixed	
Complication from cardiac tamponade	815	—	—	Fixed	18
Complication from PV stenosis	3217	—	—	Fixed	18
Outpatient initiation of amiodarone	154	—	—	Fixed	18
Amiodarone (200 mg daily, per annum)	32	—	—	Fixed	29

Continued

Table 1 Continued

Variables	Value	Low CI	High CI	Distribution	Ref
AF health state (per annum)	646	–	–	Fixed	2
NSR health state (per annum)	646	–	–	Fixed	2
Stroke (year 1)	9431	–	–	Fixed	19
Stroke (≥ 2 years, per annum)	2488	–	–	Fixed	19
Warfarin (5 mg daily, per annum)	19	–	–	Fixed	29
Aspirin (75 mg daily, per annum)	20	–	–	Fixed	29
Toxic event	1497	–	–	Fixed	30
Reversible toxicity (per day)	0.43	–	–	Fixed	29
Irreversible toxicity (50 mg daily)	158	–	–	Fixed	29
Major bleeding event	1573	–	–	Fixed	26
Minor bleeding event	87	–	–	Fixed	26

AAD, anti-arrhythmic drug; AF, atrial fibrillation; CHADS₂, congestive heart failure, hypertension, age 75, diabetes mellitus, and prior stroke; CI, confidence interval or credible interval; NSR, normal sinus rhythm; OAC, oral anticoagulants; PV, pulmonary vein; RFCA, radiofrequency catheter ablation; RR, relative risk; SE, standard error.

*Used to determine the stroke risk for NSR. The hazard ratio is applied to the CHADS₂ stroke risk scores for AF.

†RFCA procedural cost consists of total consumable (£5687), ward (£182 based on 2 days), and lab (£1979 based on 200 minutes) costs plus VAT and administration costs (Fitzpatrick A, personal communication, 2007).

short-term costs associated with RFCA include those related to the initial procedure, repeat procedures and the management of complications. In the absence of suitable national reference cost estimates for the procedure in the UK NHS, the cost of RFCA in AF was estimated based on a detailed study of the costs of consumables, ward (2 days) and lab time (200 minutes) undertaken by a UK cardiologist (Fitzpatrick A, personal communication, 2007). The costs of procedural related complications were derived from reference cost schedules.¹⁸ The short-term costs associated with AADs comprised the drug acquisition and administration costs of amiodarone including the management of adverse effects. Amiodarone (200 mg daily) was assumed to be initiated in an outpatient setting. In addition to ongoing intervention costs and other related costs (including OACs and the management of toxic events), annual costs for the main health states in the Markov model were applied. Costs for the two underlying AF health states (NSR and AF) were estimated from a recent study examining the cost of AF in the United Kingdom.² This study estimates the costs of community and hospital-based care related to AF, including general practitioner consultations, anticoagulation visits and hospital costs. In the absence of cost data which discriminated between the NSR and AF states, a conservative assumption towards RFCA was applied by applying the same annual costs to both states over the lifetime horizon. An annual cost associated with stroke was applied to the stroke state with a higher cost applied in the first year of the event.¹⁹

Quality of life adjustment

In order to estimate QALYs, it is necessary to quality adjust the period of time the average patient is alive within the model using an appropriate utility or preference score. In the absence of utility data from the trials, external data sources were sought to quantify the differential impact of the treatment regimens in terms of quality of life (QoL) and to differentiate patient health status according to the different states of the model. A comprehensive literature review was undertaken but, despite consideration of a large number of studies, no single source was identified that would provide a relevant source of baseline utility on which to apply incremental changes in utility according to health status. To encapsulate a baseline value in the model, the underlying utility of the general population, derived from a nationally representative UK sample using EQ-5D, was used as a reference point.²⁰ Patients restored to NSR

following RFCA (estimated to be associated with the largest improvement in utility) were assumed to revert to having the same QoL as the general population. For the other main health states, specific decrements were estimated (that is, AF following RFCA and NSR/AF following AADs) relative to the utility value estimated for patients restored to NSR following RFCA. These decrements were then applied to the general population utility values assumed to represent the QoL in the NSR state following RFCA. In addition, a single utility score for stroke was applied.¹⁹ Utility decrements were also applied for irreversible pulmonary toxicity, other general side effects and for major and minor bleeding events.^{21 22}

Analytical methods

The model was run probabilistically using Monte Carlo simulation and the uncertainty in the individual parameters fully characterised using the probability distributions summarised in table 1. The results are presented in two ways. First, mean lifetime costs and QALYs of both strategies are presented and their cost-effectiveness compared using incremental cost-effectiveness ratios (ICERs).²³ Second, decision uncertainty is presented as the probability that each strategy is considered the more cost-effective option for a given cost-effectiveness threshold.

The following analyses are undertaken for an average starting age of 52 years and 80% of subjects being male (typical of the RFCA population).²⁴ First, heterogeneity in patients is explored by undertaking separate analyses according to different baseline risks of stroke given by the CHADS₂ score. In the base-case analysis, CHADS₂ scores between 0 and 3 are considered. Separate analyses are also undertaken within the base-case approach assuming that QoL improvements with RFCA compared with AADs are (i) maintained for a lifetime (lifetime analysis) or (ii) maintained for a maximum of 5 years only (5-year analysis). Second, the base-case analysis uses estimates of the primary outcome (that is, freedom from arrhythmia at 12 months) from the RCT evidence alone. The impact of incorporating additional observational evidence for RFCA from the survey data and the individual case-series is investigated for a subgroup of patients with a baseline risk of stroke equivalent to CHADS₂ = 1. Third, the prognostic value of NSR is examined. The base-case assumes that restoration to NSR results in a relative risk reduction of stroke compared to AF. In an alternative scenario, the risk of stroke is assumed to be

Table 2 Cost-effectiveness results for the base-case analysis

					Probability of being cost-effective for threshold at:	
	Strategy	Mean costs (£)	Mean QALYs	ICER (£)	£20 000	£30 000
Lifetime analysis						
CHADS ₂ = 0	RFCA	25 240	12.37	7763	0.983	0.996
	AADs	14 415	10.98	–		
CHADS ₂ = 1	RFCA	26 027	12.14	7780	0.981	0.996
	AADs	15 367	10.77	–		
CHADS ₂ = 2	RFCA	26 987	11.87	7765	0.986	0.999
	AADs	16 517	10.52	–		
CHADS ₂ = 3	RFCA	28 343	11.49	7910	0.992	1.000
	AADs	18 107	10.19	–		
5-year analysis						
CHADS ₂ = 0	RFCA	25 251	11.35	27 745	0.091	0.577
	AADs	14 429	10.96	–		
CHADS ₂ = 1	RFCA	26 016	11.18	25 510	0.165	0.686
	AADs	15 352	10.76	–		
CHADS ₂ = 2	RFCA	26 972	10.97	23 202	0.265	0.786
	AADs	16 499	10.52	–		
CHADS ₂ = 3	RFCA	28 366	10.67	20 831	0.418	0.881
	AADs	18 133	10.18	–		

AAD, anti-arrhythmic drug; CHADS₂, congestive heart failure, hypertension, age 75, diabetes mellitus, and prior stroke; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RFCA, radiofrequency catheter ablation.

identical for both treatments and therefore the subsequent cost-effectiveness is based entirely on the symptomatic benefit of RFCA compared to AADs. Fourth, the base-case analysis which applies separate utility estimates to patients in the NSR and AF health states according to treatment received is relaxed and no differential impact on QoL according to treatment received is assumed—that is, separate utility estimates are assigned to NSR and AF (NSR > AF) but assumed to be the same for RFCA and AADs. Fifth, the annual transition probability of reversion back to AF for patients receiving RFCA was increased to 5–15% per annum. Any additional benefit or reduction in costs assigned to NSR relative to AF is only maintained in the long term if patients continue to remain free of arrhythmia.

RESULTS

Base-case analysis

Table 2 presents the base-case results according to the baseline risk of stroke and maintenance time of QoL improvements. For

the lifetime analysis, the ICER associated with RFCA compared with AADs is between £7763 and £7910 for each additional QALY across the different CHADS₂ scores. The probability that RFCA is cost-effective at thresholds of £20 000 and £30 000 per QALY varies from 0.981 to 0.992 and from 0.996 to 1.000, respectively, across the separate risk groups. Hence there is little uncertainty that RFCA is the optimal treatment if QoL benefits are maintained over a lifetime and the NHS is prepared to pay this amount.

For the 5-year analysis, the ICER associated with RFCA compared with AADs is between £20 831 and £27 745 per QALY gain across the separate groups, with the cost-effectiveness appearing more favourable the higher the risk of stroke. The probability that RFCA is cost-effective at thresholds of £20 000 and £30 000 per QALY is much lower (ranging from 0.091 to 0.418 and from 0.577 to 0.881, respectively) compared to the lifetime analysis. Hence, the cost-effectiveness of RFCA is less clear if the QoL improvements are maintained for a maximum of 5 years only.

Table 3 Cost-effectiveness of RFCA for alternative scenarios (for CHADS₂ = 1)

	Lifetime analysis			5-year analysis		
	ICER (£)	Probability CE at £20 000	Probability CE at £30 000	ICER (£)	Probability CE at £20 000	Probability CE at £30 000
Source of effectiveness evidence						
RCTs and worldwide survey ^a	7814	0.988	1.000	25 623	0.156	0.701
RCTs and case-series	7851	0.975	0.999	25 573	0.184	0.634
Prognostic impact of NSR						
Prognosis for NSR and AF equivalent	9327	0.977	0.996	37 997	0.027	0.204
Utilities for health states						
No differential impact by treatment	12 840	0.682	0.963	32 524	0.008	0.399
Annual probability of reversion back to AF after RFCA						
(a) 5%	7999	0.982	0.999	26 969	0.132	0.618
(b) 10%	8401	0.966	0.970	29 910	0.075	0.441
(c) 15%	8703	0.954	0.944	32 035	0.060	0.374

AF, atrial fibrillation; CE, cost-effectiveness; ICER, incremental cost-effectiveness ratio; NSR, normal sinus rhythm; QALY, quality-adjusted life year; RCT, randomised controlled trials; RFCA, radiofrequency catheter ablation.

Alternative scenarios

Table 3 presents the results for alternative scenarios. The inclusion of observational and case-series evidence for RFCA results in only a marginal increase in the ICER for both the lifetime and 5-year analysis. The prognostic impact of NSR results in a greater influence on the cost-effectiveness of RFCA. In the lifetime analysis, the ICER increased from £7780 (base-case) to £9237 per additional QALY, while for the 5-year analysis it increased from £25 510 to £37 997. These results would indicate that the cost-effectiveness of RFCA requires either the QoL benefits to be maintained for more than 5 years and/or the assumption that NSR has prognostic value in preventing the risk of stroke. The alternative assumption of no differential impact on QoL according to treatment received, except through entry into the NSR and AF health states, had an impact on the cost-effectiveness of RFCA. The ICER of RFCA in the lifetime analysis increased to £12 840 per additional QALY, while the ICER for the 5-year analysis increased to £32 524 per additional QALY. Consequently, the results indicate that the cost-effectiveness of RFCA is sensitive to the assumption of a differential utility estimate for NSR and AF according to treatment received. If it is believed that RFCA confers additional QoL benefits to patients following a successful treatment compared to patients receiving AADs and/or that the QoL benefits are maintained for more than 5 years, then the cost-effectiveness of RFCA is less uncertain. Increasing the long-term risk of recurrent AF following RFCA results in a marginal increase in the ICER in the lifetime analysis. In the 5-year analysis, when the annual probability is increased to 15%, the ICER is above the range considered to be cost-effective.

DISCUSSION

Only one previous study has examined the cost-effectiveness of RFCA for AF.⁴ This study is based on a US population and as such it has a number of limitations for decision-making in the UK NHS. For example, in the United Kingdom the pattern of care and number of cardiologists undertaking RFCA differs from the United States. In addition, the majority of patients referred for RFCA therapy in the United Kingdom have failed previous AAD therapy and, therefore, unlike the United States, RFCA is unlikely to be given as a possible first-line therapy. The present study provides a comprehensive assessment of the cost-effectiveness of RFCA for patients refractory to AADs in the UK NHS. Unlike the one previous study,⁴ this analysis attempts to capture the additional symptomatic benefits in addition to any additional prognostic benefit.

The results of the analysis presented here demonstrate that the long-term maintenance of QoL benefits of RFCA is central to the cost-effectiveness estimates. If the benefits are maintained over the lifetime of the patient, RFCA is likely to be highly cost-effective based on the cost-effectiveness thresholds used by the National Institute for Health and Clinical Excellence (£20 000 to £30 000 per additional QALY).²⁵ This conclusion also holds across a range of different baseline risks of stroke. The finding contrasts with the previous study,⁴ where RFCA was found to be cost-effective only in those at high risk of stroke and in certain patients groups with moderate stroke risk. This difference highlights the importance of symptomatic QoL benefits. If the assumption of lifetime benefits is considered unrealistic then the question of how long the benefits are likely to be maintained becomes a key consideration. The results of the 5-year analysis suggest that the cost-effectiveness of RFCA is not clearcut with an ICER of £25 510 falling just below the upper bound of conventional thresholds. Any shorter duration

of QoL benefits would result in an ICER above acceptable thresholds (for example, 4-year duration results in an ICER = £30 102; 3-year duration, ICER = £37 385; 2-year duration, ICER = £49 355).

The results from the different scenarios suggest that the overall cost-effectiveness of RFCA for the shorter duration of benefits is likely to be determined by a number of factors. These include: (i) whether there are additional prognostic benefits associated with NSR (that is, via a reduction in the long-term risk of stroke); and (ii) the magnitude of the QoL difference between RFCA and AADs. The importance of these factors will decline the longer any QoL advantage associated with RFCA is maintained beyond 5 years.

While the cost-effectiveness model attempted to quantify the potential QoL gains that could be achieved using RFCA through symptomatic improvements and reduction in the longer-term risk associated with major clinical events, a number of limitations to the analysis should be noted. First, the QoL estimates applied in the model remain highly uncertain. To date no single study has attempted to quantify the impact of RFCA using a generic, utility measure such as the EQ-5D. This represents a major limitation when trying to establish the cost-effectiveness of an intervention in the NHS. In the absence of these data, alternative approaches were used to attempt to map between the QoL measures that have been used (SF-36) and a utility based measure (EQ-5D). The process of mapping between these different instruments itself introduces a source of uncertainty. However, a number of separate scenarios were considered in the model and these demonstrated that the overall results remained fairly robust to the different estimates, suggesting that the duration of any benefits is likely to be the key determinant of cost-effectiveness. Second, the evidence of the longer-term benefits of RFCA (that is, for periods potentially beyond 5 years) is lacking and hence extrapolating the potential benefits reported over shorter time horizons becomes increasingly uncertain. The model results clearly demonstrate that the cost-effectiveness estimates are extremely sensitive to the duration over which these benefits are likely to be maintained. Third, in the absence of direct evidence from RCTs, the AFFIRM study was used to quantify the potential differential stroke risk for NSR/AF but this study did not involve RFCA. Fourth, the decision model only considers the cost-effectiveness of RFCA in patients with predominantly paroxysmal AF.

In conclusion, the analysis suggests that RFCA is potentially cost-effective for the treatment of paroxysmal AF in patients predominantly refractory to AAD therapy if the QoL benefits are maintained for more than 5 years. These findings remain subject to important uncertainties regarding both the magnitude of QoL benefits and the prognostic value of restoring NSR achieved with RFCA.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme. The views expressed are those of the authors who are also responsible for any errors.

Competing interests: None.

REFERENCES

1. Steinberg JS. Atrial fibrillation: an emerging epidemic? *Heart* 2004;**90**:239–40.
2. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. *Heart* 2004;**90**:286–92.
3. National Institute for Health and Clinical Excellence. *Percutaneous radiofrequency ablation for atrial fibrillation*. London: NICE, 2006:1–2.
4. Chan PS, Vijan S, Morady F, et al. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. *J Am Coll Cardiol* 2006;**47**:2513–20.

5. **National Institute for Clinical Excellence.** *Guidance to the methods of technology appraisal.* London: NICE, 2004.
6. **Krittayaphong R,** Raungrattanaamporn O, Bhuripanyo K, *et al.* A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. *J Med Assoc Thai* 2003;**86**(suppl 1):S8–16.
7. **Pappone C,** Augello G, Sala S, *et al.* A randomised trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. *J Am Coll Cardiol* 2006;**48**(11).
8. **Wazni OM,** Marrouche NF, Martin DO, *et al.* Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA* 2005;**293**:2634–40.
9. **Cappato R,** Calkins H, Chen SA, *et al.* A worldwide survey on the methods, efficacy, and safety of catheter ablation of atrial fibrillation. *Circulation* 2004;**110**:2524.
10. **Pappone C,** Rosanio S, Augello G, *et al.* Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. *J Am Coll Cardiol* 2003;**42**:185–97.
11. **Roy D,** Talajic M, Dorian P, *et al.* Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *N Engl J Med* 2000;**342**:913–20.
12. **Gage BF,** Waterman AD, Shannon W, *et al.* Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;**285**:2864–70.
13. **Lip GY,** Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. *Thromb Res* 2006;**118**:321–33.
14. **Sherman DG,** Kim SG, Boop BS, *et al.* Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. *Arch Intern Med* 2005;**165**:1185–91.
15. **Nieuwlaat R,** Capucci A, Lip GYH, *et al.* Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2006;**27**:3018–26.
16. **Dennis MS,** Burn JP, Sandercock PA, *et al.* Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project *Stroke* 1993;**24**:796–800.
17. **Government Actuary's Department.** *Life Tables* 2007.
18. **Department of Health.** *Reference costs.* Leeds: DH, 2005.
19. **Jones L,** Griffin S, Palmer S, *et al.* Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. *Health Technol Assess* 2004;**3**:1–196.
20. **Kind P,** Hardman G, Macran S. *UK population norms for EQ-5D.* Centre for Health Economics discussion paper 172. York: Centre for Health Economics, University of York, 1999.
21. **Sullivan P,** Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the US. *Med Decis Making* 2006;**26**:410–420.
22. **Owens DK,** Sanders GD, Harris RA, *et al.* Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. *Ann Intern Med* 1997;**126**:1–12.
23. **Johannesson M,** Weinstein S. On the decision rules of cost-effectiveness analysis. *J Health Econ* 1993;**12**:459–67.
24. **Bourke JP,** Dunuwille A, O'Donnell D, *et al.* Pulmonary vein ablation for idiopathic atrial fibrillation: six month outcome of first procedure in 100 consecutive patients. *Heart* 2005;**91**:51–7.
25. **Devlin N,** Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis *Health Econ* 2004;**13**:437–52.
26. **National Institute for Health and Clinical Excellence.** *Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 36.* London: NICE, 2006.
27. **Berkowitsch A,** Neumann T, Kurzidim K, *et al.* Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence. *Europace* 2003;**5**:351–5.
28. **Rienstra M,** Van Gelder IC, Hagens VE, *et al.* Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. *Eur Heart J* 2006;**27**:357–64.
29. **British Medical Association, Royal Pharmaceutical Society of Great Britain.** *British National Formulary: No 53, March 2007.* London: BMA, Royal Pharmaceutical Society of Great Britain, 2007.
30. **Buxton M,** Caine N, Chase D, *et al.* A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and the modelling of cost-effectiveness and cost-utility for these groups in a UK context. *Health Technol Assess* 2006;**10**:1–180.